FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

ashington,	D.C.	20549	

STATEMENT	OF CHANGE	ES IN BENEFICIAI	L OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ENRIGHT PATRICK G				2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]								ck all app	tionship of Reporting all applicable) Director Officer (give title		rson(s) to Is 10% O	wner				
(Last) 5TH FL, WATERI		3. Date of Earliest Transaction (Month/Day/Year) 11/12/2020									belov			below)						
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)	Form	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Sta	ate) (Z	<u>Z</u> ip)																	
		Table	I -	Non-Deriva	tive	Secu	rities	Ac	quir	ed, I	Dis	posed (of, or	Bene	ficial	ly Own	ed			
Date			2. Transaction Date (Month/Day/Ye	ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Tı C	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			nd 5)	Secu Bene Owne Follo	ficially d ving	Forr (D) o	n: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								С	ode	v	Am	nount	(A) or (D)) or Price		Trans	Reported Transaction(s) (Instr. 3 and 4)			
Ordinary	Ordinary Shares 11/12/2020)				S ⁽¹⁾		3,223 D		D	\$145.8102 ⁽²⁾		2(2) 27,074			D		
Ordinary	Shares			11/12/2020)				S ⁽¹⁾		5	5,083	D	D \$147.0032 ⁽³		21,991			D	
Ordinary Shares 11/12/2020)			S ⁽¹⁾]	1,623	D	\$147.	\$147.6122 ⁽⁴⁾		20,368		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exe if a	Deemed acution Date, ny onth/Day/Year)		saction (Instr.	5. Nu of Deriv Secur Acqu (A) or Dispo of (D) (Instr	ative rities ired rosed	Ex	piratio	e Exercisable and Ition Date h/Day/Year)		Ame Sec Und Der Sec	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Price of erivative ecurity nstr. 5)		,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	· v	V (A) (D)			Date Exercisab		Expiratio Date	Expiration Date Title		er es					

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$145.36 to \$146.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$146.559 to \$147.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$147.56 to \$147.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

By: /s/Doris Choi, as attorney in fact For: Patrick G Enright

** Signature of Reporting Person Date

11/13/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.